Vivos Therapeutics, Inc. (VVOS) Stock Analysis

Company Overview

The market values Vivos Therapeutics, Inc. (VVOS) at $3.75M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 268.

The 52-week range on file runs from $0.16 to $4.13. The most recent close on file for VVOS is $0.19, dated September 4, 2026. That is +$0.01 (+6.29%) against the previous close. The latest close sits 17.72% above that 52-week low.

Financial Health

In fiscal 2025, Vivos Therapeutics, Inc. reported revenue of $17.44M. Against the prior fiscal year total of $15.03M, that is a change of +16.05%. The same year closed with a net loss of $21.23M. Profit margin runs at −121.79%. That is 120.1 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −2.

Across the 4 fiscal years on file, revenue moves from $16.02M in 2022 to $17.44M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 0.18 times revenue. On price-to-sales that is 0.1 times the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −95.77%. Measured over 5 years, that is −72.90% a year compounded. Daily returns over the trailing 5 years annualize to a volatility of 399.67%.

Growth & Income

The record shows no dividend for VVOS.

Across the complete calendar years on file, 2023 returned +23.78% and 2022 returned −82.13%. Of the 5 complete calendar years on file, 1 finished higher. So far in 2026 the price is −90.84%.